We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




ICDs Can Save Many Lives

By HospiMedica staff writers
Posted on 01 Feb 2005
A new landmark study has shown that the use of an implantable cardioverter-defibrillator (ICD) in patients with heart failure can reduce deaths by 23%. More...
The results were reported in the January 20, 2005, issue of The New England Journal of Medicine.

The study involved 2,521 patients in 150 medical centers in Canada, New Zealand, and the United States with moderate heart failure and poor heart-pumping function who had not experienced sudden cardiac arrest (SCA). An ICD shocks the heart out of a rapid, chaotic heart rhythm that otherwise can lead to death within minutes. The study compared the benefits of ICDs with those of amiodarone, a commonly used heart medication.

The study was sponsored by the U.S. National Institutes of Health (Bethesda, MD, USA), with funding and therapy donations from Wyeth Pharmaceuticals and Medtronic, Inc. After the study was finished, Medtronic, a developer and marketer of ICDs, offered free ICDs to all interested participants who had been randomized to a non-ICD study arm. Implantable defibrillators have been approved for use since the late 1980s, but primarily for the 5% of patients who had already survived an SCA episode.

"This is the first time we have concrete evidence that many people with heart failure will die from sudden cardiac arrest if they don't have an implanted defibrillator,” said Richard Luceri, M.D., of Florida Arrhythmia Consultants/Holy Cross Hospital (Fort Lauderdale, FL, USA). "People with heart failure can be evaluated with a simple test called an echocardiogram to determine if they are at risk for sudden cardiac arrest.”




Related Links:
U.S. National Institutes of Health

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.